Sacituzumab Govitecan Promising for Advanced Endometrial Cancer

WEDNESDAY, Aug. 14, 2024 – Sacituzumab govitecan (SG), an antibody-drug conjugate that targets trophoblast cell-surface antigen 2 (Trop-2), has demonstrated promising efficacy for patients with advanced endometrial cancer (EC), according to findings from a phase 2 study published in the Journal of Clinical Oncology.

The study, led by Dr. Alessandro D. Santin from the Yale School of Medicine, aimed to evaluate the efficacy and safety of SG in patients with advanced EC. The phase 2 basket study included eligible patients who received SG at a dosage of 10 mg/kg on days 1 and 8 of a three-week cycle. The median follow-up period for the study was 5.8 months, with the primary endpoint being the objective response rate.

A total of 41 patients were enrolled at the time of data extraction. On average, each patient had undergone three previous therapies, and 85 percent had received both chemotherapy and immunotherapy prior to the study. The researchers observed an objective response rate of 22 percent and a clinical benefit rate of 32 percent. The median duration of response was reported to be 8.8 months, while the median progression-free survival was 4.8 months.

An exploratory analysis of Trop-2 expression was conducted retrospectively on 39 of the patients. Results indicated a high level of Trop-2 protein expression in endometrial cancer tumors, although the correlation between Trop-2 expression and treatment efficacy was limited.

The study also reported that 73 percent of patients experienced grade 3 or higher treatment-related adverse events (TRAEs). The discontinuation rate due to TRAEs was relatively low at 5 percent. Notably, there were two patient deaths during the study, but these were deemed unrelated to SG treatment.

Based on the positive outcomes observed in this phase 2 trial, the authors announced plans for a randomized phase III study to further investigate SG's potential as a treatment for advanced EC.

The study had several authors with disclosed connections to pharmaceutical companies, including Gilead Sciences, which manufactures sacituzumab govitecan and provided funding for the research.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!